Will 2024 Be Easier on the Eyes? Will 2024 Be Easier on the Eyes?
Longer-acting drugs, novel implants, and oral and topical agents that aim to solve the burden of frequent injections and office visits for retinal disease are on the horizon.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - February 29, 2024 Category: Drugs & Pharmacology Tags: Ophthalmology Source Type: news
Don't get burned: Expert tips and tricks on MRI safety
How can MRI staff reduce the impact of radiofrequency-induced heating? Are tattoos and implantable medical devices safe? How can quenching be avoided? What are the special risks in 7-tesla MRI? A prize-winning RSNA 2023 exhibit addressed these and other questions.
"While we are familiar with medical safety and ethics principles when errors occur, the culture of blaming parties is still prevalent," noted Ana Paula Santos Lima, MD, assistant professor of radiology at the University of Washington, and colleagues. "Everyone makes mistakes; it's crucial to minimize risks. It's not always direct staff at fault."
System-wide vu...
Source: AuntMinnie.com Headlines - December 11, 2023 Category: Radiology Authors: Philip Ward Tags: MRI Source Type: news
New clinical and real-world data for Roche ’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss
Late-breaking post-hoc data indicateVabysmo leads to less fibrosis, which may negatively impact vision, thanaflibercept in people with diabetic macular edema (DME)Real-world data reinforce that first-lineVabysmo use improves outcomes and extends treatment intervals rapidly during the first four months for people withneovascular or ‘wet’ age-related macular degeneration (nAMD) and DMEClinical data reiterateVabysmo ’s positive anatomical outcomes, including reduced blood vessel leakage in the macula and greater and faster retinal fluid controlVabysmo is currently approved in over 70 countries to treatnAMD and DME, with...
Source: Roche Media News - July 20, 2023 Category: Pharmaceuticals Source Type: news
New clinical and real-world data for Roche ’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss
Late-breaking post-hoc data indicateVabysmo leads to less fibrosis, which may negatively impact vision, thanaflibercept in people with diabetic macular edema (DME)Real-world data reinforce that first-lineVabysmo use improves outcomes and extends treatment intervals rapidly during the first four months for people withneovascular or ‘wet’ age-related macular degeneration (nAMD) and DMEClinical data reiterateVabysmo ’s positive anatomical outcomes, including reduced blood vessel leakage in the macula and greater and faster retinal fluid controlVabysmo is currently approved in over 70 countries to treatnAMD and DME, with...
Source: Roche Investor Update - July 20, 2023 Category: Pharmaceuticals Source Type: news
Serious Complications Uncommon After Primary Lens Implantation in Children
(MedPage Today) -- A third of intraocular lens (IOL) implants for nontraumatic glaucoma in children required reoperation for visual axis opacification (VAO) within 5 years, most often in eyes that did not have anterior vitrectomy, a large cohort... (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - June 23, 2023 Category: Pediatrics Source Type: news
Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Investigational Single Tablet Combination Therapy of Macitentan and Tadalafil for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
RARITAN, NJ, May 30, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of an investigational single tablet combination therapy of macitentan 10mg and tadalafil 40mg (M/T STCT) for the long-term treatment of pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) in adult patients with WHO functional class (FC) II-III.[1] The application is based on positive data from the Phase 3 A DUE study, which met its primary endpoint and demonstrated that M/T STCT si...
Source: Johnson and Johnson - May 30, 2023 Category: Pharmaceuticals Source Type: news
Johnson & Johnson Vision Introduces All Purpose EDOF, TECNIS Symfony OptiBlue IOL, the Latest PC-IOL Powered by InteliLight Technology
IRVINE, Calif. – Sept. 27, 2022 – Johnson & Johnson Vision,** a global leader in eye health and part of Johnson & Johnson MedTech,*** today announced availability of our presbyopia-correcting intraocular lens (PC-IOL) powered by InteliLight technology https://www.jnjvisionpro.com/intelilight , TECNIS Symfony OptiBlue IOL. This extended depth-of-focus (EDOF) lens expands presbyopia correction to more patients and joins TECNIS Synergy IOL, a high-performance hybrid lens designed for spectacle independence****, in the InteliLight portfolio. These two complementary products deliver superior* contrast and low-light ...
Source: Johnson and Johnson - September 28, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
How Pharma can win back its online voice
Customer engagement now starts online. Around 80% of patients Google a recommended or newly-prescribed medication. And doctors routinely use search engines too – to stay up to date, to verify assumptions and so on.Indeed, it may be no exaggeration to say that the answers found online are possibly the biggest influence on patients and HCPs today. Understanding their real-world digital information experience is, therefore, critical to identifying the content influencing their behaviour.
But exploring what they really see and hear via search may shock you.Despite pharma ’s investment in evidence-based, balanced and a...
Source: EyeForPharma - July 5, 2022 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
ADRIAN MONTI: New implant to treat glaucoma - and get your cataracts done at the same time!
Roger Pledge, 76, from Colchester, Essex, was the first in the UK to have a new type of implant fitted in both eyes to combat it, as he tells Adrian Monti. (Source: the Mail online | Health)
Source: the Mail online | Health - July 5, 2022 Category: Consumer Health News Source Type: news
Brain Implant Helps Completely'Locked-In' Man Communicate
TUESDAY, March 22, 2022 -- Unable to move a single muscle, even to open your eyes. Completely locked into your own body, yet fully conscious and aware.
Lou Gehrig ' s disease— amyotrophic lateral sclerosis (ALS)— is a nightmare in its... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 22, 2022 Category: General Medicine Source Type: news
‘Emotional moment’: locked-in patient communicates with family via implant
New technology allows patients to communicate but at slow paceA completely locked-in patient is able to type out words and short sentences to his family, including what he would like to eat, after being implanted with a device that enables him to control a keyboard with his mind.The findings, published in Nature Communications,overturn previous assumptions about the communicative abilities of people who have lost all voluntary muscle control, including movement of the eyes or mouth, as well as giving a unique insight into what it ’s like to be in a “locked in” state.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - March 22, 2022 Category: Science Authors: Linda Geddes Tags: Science Health World news Motor neurone disease Source Type: news
Bionic eyes: Obsolete tech leaves patients in the dark
The retinal-implant manufacturer has shifted its focus, leaving users with little or no support. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - February 17, 2022 Category: Consumer Health News Source Type: news
Roche ’s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness
Basel, 21 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from two identically designed global phase III studies, YOSEMITE and RHINE, evaluating its investigational bispecific antibody, faricimab, in people living with diabetic macular edema (DME). Both studies met their primary endpoint and showed that faricimab given every eight weeks and at personalised dosing intervals of up to 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks. Faricimab was generally well-tolerated, with no new safety signals identified. The studies each h...
Source: Roche Investor Update - December 21, 2020 Category: Pharmaceuticals Source Type: news
Roche ’s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness
Basel, 21 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from two identically designed global phase III studies, YOSEMITE and RHINE, evaluating its investigational bispecific antibody, faricimab, in people living with diabetic macular edema (DME). Both studies met their primary endpoint and showed that faricimab given every eight weeks and at personalised dosing intervals of up to 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks. Faricimab was generally well-tolerated, with no new safety signals identified. The studies each h...
Source: Roche Media News - December 21, 2020 Category: Pharmaceuticals Source Type: news
Best Practices for Human-Centric Design of Medical Devices
Medical devices designed to accommodate human variability present a growing opportunity for the healthcare and life sciences industries. Historically, medicine has solved many of the “simple†issues first: how to fix a broken leg has been known for centuries! But today we have treatments that didn’t even exist a generation ago, such as the use of stents and replacement valves for heart disease. These devices address a more limited cohort of people and are most successful when designed to be patient-specific. The cohorts themselves must also be further defined to account...
Source: MDDI - May 5, 2020 Category: Medical Devices Authors: Kristian Debus Tags: Design Source Type: news
